Claes Ohlsson - Biography#
Dr Ohlsson has made significant contributions to the osteoporosis field with a special focus on “the hormonal regulation of bone growth and metabolism, and more recently, the genetics of bone mass and fractures”. During his whole career, he has combined his scientific work with clinical work as a senior consultant with board certificate in clinical pharmacology at the Sahlgrenska University Hospital. His translational research aims to improve the prevention, diagnosis and treatment of osteoporosis, often starting from unique Swedish cohort studies followed by mechanistic molecular studies. He has identified genetic, non-invasive imaging and biochemical markers of osteoporosis and fracture susceptibility and his subsequent mechanistic studies have unravelled novel osteoporosis drug targets. Starting from a human genetic finding, he identified a new mechanism for the regulation of fracture susceptibility. Furthermore, he demonstrated that the gut microbiota regulates bone mass and this finding opened up the new research field osteomicrobiology. He is the author of >600 articles.
Education
- 1990, M.D. (Swedish ”läkarexamen”), University of Gothenburg (GU), Sweden
- 1993, Ph.D., Department of Physiology, GU
- 1996 - 1997, Postdoctoral work, National Institutes of Health, NIDDK, Bethesda, MD, USA
Clinical certificates
- 1994, Registered Physician (legitimerad läkare)
- 2003, Board certificate in Clinical Pharmacology
Publication summary
- 602 peer-reviewed original publications (45 as first author and 162 as senior, including shared positions)
- Number of articles with impact factor ≥20 = 36 (Including articles in New England Journal of Medicine, Nature [x6], Nature Medicine [x3], Nature Genetics [x9], Lancet [x3], JAMA, BMJ, Lancet Diabetes and Endocrinology [x3], Annals of Internal Medicine, Alzheimer’s & Dementia, European Heart Journal, Nature Reviews Endocrinology [x2]], J Amer Coll Cardiol [x3], Gut)
- Number of articles with impact factor ≥10 = 90
